

Duchenne Muscular Dystrophy Market Size Predicted to Hit USD 2.1 billion by 2031 at 4.7% CAGR, Says AMR

Rise in the incidence of the Duchenne muscular dystrophy (DMD) and surge in need for better healthcare services drive the growth of the global market.

PORTLAND, OR, UNITED STATES, January 29, 2025 /EINPresswire.com/ -- Allied Market Research published a report, titled, "[Duchenne Muscular Dystrophy Market](#) by Therapeutic Area, (Molecular-based Therapies and Steroid Therapy), and Distribution

Channel (Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Pharmacies): Global Opportunity Analysis and Industry Forecast, 2022-2031". Duchenne Muscular Dystrophy (DMD) Market Size was Valued at USD 1.3 billion in 2021 and is Projected to Garner USD 2.1 billion by 2031, registering a CAGR of 4.7% from 2022 to 2031.

This report provides a comprehensive overview of the Duchenne Muscular Dystrophy Market, including an in-depth analysis of market trends, key segments, investment opportunities, value chain analysis, regional landscape, and competitive scenarios. It offers valuable insights for established market players, new entrants, investors, and other stakeholders to devise effective strategies and make informed decisions to enhance their market position. The report is a valuable resource for anyone seeking to gain a deeper understanding of the Duchenne Muscular Dystrophy Market and its growth potential in the future.

Rise in the incidence of the Duchenne muscular dystrophy (DMD) and surge in need for better healthcare services drive the growth of the global Duchenne muscular dystrophy market. However, inflated cost of treatments for Duchenne muscular dystrophy restricts the market growth. On the other hand, increase in government spending on the pharmaceutical and biotechnology sectors in developing countries, the development of healthcare infrastructure, and rise in demand for innovative treatments for Duchenne muscular dystrophy present new



opportunities in the coming years.

□□□ □□□□□□ □□□ □□□□□□ □□□□ □□□□□□ □□□□:

<https://www.alliedmarketresearch.com/request-sample/A15646>

□□□ □□□□□□□□□ □□ □□□□□□□□ □□□□□□□□ □□□□□□□□□□ (□□□)

- F Hoffmann-La Roche AG
- FibroGen, Inc
- GlaxoSmithKline plc
- Italfarmaco S.p.A.
- Nippon Shinyaku Co., Ltd
- Pfizer Inc.
- PTC Therapeutics
- Santhera Pharmaceuticals Inc
- Sarepta therapeutics
- Wave life sciences ltd.
- ABBOTT LABORATORIES

□□□□□□□□ □□□□□□□□ □□□□□□□□□□ (□□□) □□□□□□ □□□□ □□□□□□□□□□□□□□: –

Based on therapeutic area, the molecular-based therapies segment held the highest market share in 2021, accounting for around three-fifths of the global Duchenne muscular dystrophy market, and is estimated to maintain its leadership status throughout the forecast period. In addition, the same segment is projected to manifest the highest CAGR of 5.0% from 2022 to 2031, owing to R & D activities for exon skipping drugs, strong product pipeline and significant product launch by key players. The report also discusses steroid therapy segment.

Based on distribution channel, the hospital pharmacies segment accounted for the largest share in 2021, contributing to more than three-fifths of the global Duchenne muscular dystrophy market, and is projected to maintain its lead position during the forecast period. This is owing to significant rise in the number of diagnosis through hospitals. However, the drug store & retail pharmacies segment is expected to portray the largest CAGR of 5.4% from 2022 to 2031, owing to the rise in the approval of drugs and their availability in drug store & retail pharmacies.

Based on region, North America held the highest market share in terms of revenue in 2021, accounting for more than half of the global Duchenne muscular dystrophy market, and is likely to dominate the market during the forecast period. This is owing to technological advancements in Duchenne muscular dystrophy treatment and presence of key players & robust hospital infrastructure in the region.

However, the Asia-Pacific region is expected to witness the fastest CAGR of 5.9% from 2022 to 2031. This is owing to rise in cases of Duchenne muscular dystrophy, approval of drugs,

development of healthcare infrastructure, and increase in investments projects in the region.

□□□□□□□□ □□□ □□□□□□: <https://www.alliedmarketresearch.com/purchase-enquiry/16015>

Key Benefits For Stakeholders

- The report provides an in-depth analysis of the Duchenne muscular dystrophy market size along with the current trends and future estimations to elucidate imminent investment pockets.
- It offers market analysis from 2022 to 2031, which is expected to enable stakeholders to capitalize on prevailing opportunities in the Duchenne muscular dystrophy market.
- A comprehensive analysis on region assists to understand the regional market, facilitate strategic business planning, and determine prevailing opportunities.
- The profiles and growth strategies of key players are thoroughly analyzed to understand competitive outlook of the global Duchenne muscular dystrophy treatment market growth.

□□□ □□□□□□ □□□□□□□□ □□□□□□□□ □□□ □□□□□□ □□ □□□□□ □□□□□□□□□ □□□□□□□□:

- Which are the driving factors responsible for the growth of market?
- Which are the roadblock factors of this market?
- What are the new opportunities, by which market will grow in coming years?
- What are the trends of this market?
- Which are main factors responsible for new product launch?
- How big is the global & regional market in terms of revenue, sales and production?
- How far will the market grow in forecast period in terms of revenue, sales and production?
- Which region is dominating the global market and what are the market shares of each region in the overall market in 2022?
- How will each segment grow over the forecast period and how much revenue will these segments account for in 2030?
- Which region has more opportunities?

□□ □□□□□□ □□□□□□□□

- North America
(U.S., Canada, Mexico)
- Europe
(Germany, France, UK, Italy, Spain, Rest of Europe)
- Asia-Pacific
(Japan, China, India, Rest of Asia-Pacific)
- LAMEA
(Brazil, Saudi Arabia, South Africa, Rest of LAMEA)

□□□□□□□□ □□□□□□□□:

David Correa

USA/Canada (Toll Free): +1-800-792-5285, +1-503-894-6022

help@alliedmarketresearch.com

□□□□ □□

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of “Market Research Reports” and “Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

David Correa

Allied Market Research

+ + +1 800-792-5285

[email us here](#)

Visit us on social media:

[Facebook](#)

[X](#)

[LinkedIn](#)

[YouTube](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/781228662>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.